BGPT: Paper Review: LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer

Fuel Your Discoveries

Quick Explanation Copied

Core claim: This paper argues that LGR5 gain enhances cervical cancer stem-like phenotypes (tumorsphere formation, differentiation capacity, and in vivo tumor initiation), increases cisplatin resistance, and promotes migration/invasion/EMT—mechanistically linked to Wnt/β-catenin modulation.

All extracted quantitative claims below are grounded directly in the paper text.

Long Explanation

Cell Death & Disease • 2017-09-07

LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer

DOI: 10.1038/cddis.2017.393

1) Visualized evidence map (what was perturbed → what changed)

Perturbation logic used in the paper:

LGR5 overexpression (pCAG-AcGFP-LGR5) and LGR5 knockdown (shRNA) in SiHa and HeLa cervical cancer cell lines.
Readouts included: tumorsphere/self-renewal; limiting-dilution xenograft tumor initiation frequency; in vitro & in vivo differentiation/hierarchy via sorted populations; cisplatin response by MTT; migration/invasion and EMT markers; stemness TFs; Wnt/β-catenin modulation via DKK-1 and CHIR-99021.

2) Key quantitative readouts (reconstructed from the provided text)

Note: The paper text provides several explicit percentages/fold-changes/frequencies; where exact replicate-level statistics are not given in the supplied text, I only visualize the reported summary values.

Reported fractions: SiHa-AcGFP ~1.7%, SiHa-LGR5 ~80.1%, SiHa-shLGR5 ~0.8%; HeLa-AcGFP ~1.3%, HeLa-LGR5 ~35.6%, HeLa-shLGR5 ~0.5%.

The text reports 8 mice per group and tumor formation at doses 10^4, 10^3, 10^2 for LGR5+ and LGR5− populations from SiHa and HeLa.

Reported tumor-initiating frequencies: SiHa LGR5+ 1/36 vs SiHa LGR5− 1/627; HeLa LGR5+ 1/46 vs HeLa LGR5− 1/6276.

The text reports: in vitro, ~19.0% of modulated SiHa LGR5+ cells become LGR5− (81.0% remain LGR5+), and ~47.0% of modulated HeLa LGR5+ become LGR5− (53.0% remain LGR5+). For LGR5− populations, ~99%+ remain LGR5− (SiHa LGR5− retains ~99.0% LGR5−; HeLa LGR5− retains ~99.1%).

3) Mechanistic claims & pathway tests (what makes Wnt/β-catenin plausible vs uncertain)

Stemness TF modulation: LGR5 perturbations are reported to change levels of stemness-associated transcription factors (e.g., OCT4, NANOG, KLF4, ALDH, BMI1) and EMT-related proteins (E-cadherin, vimentin, Snail).
Wnt/β-catenin pathway linkage via pharmacologic tools: DKK-1 decreases tumorsphere-forming efficiency in LGR5-overexpressing cells, while CHIR-99021 increases tumorsphere-forming efficiency in LGR5-knockdown cells.

Skeptical nuance: Pharmacologic Wnt modulators can have pleiotropic effects. In the supplied excerpt, the pathway evidence is supportive but does not (for example) show rescue of downstream effectors independent of β-catenin, nor does it detail transcriptomic confirmation of Wnt targets.

Directed network (paper’s causal story as a graph)

The graph reflects the paper’s presented dependency chain: LGR5 modulation → stemness traits/hierarchy → tumor initiation and chemoresistance; and LGR5 → Wnt/β-catenin modulation supported by β-catenin changes and functional sphere readouts under DKK-1/CHIR-99021.

4) Chemoresistance: what is shown and what is uncertain

Cisplatin dose-response (MTT, 24h): LGR5-overexpressing SiHa and HeLa cells show higher viability at cisplatin concentrations ≥ 6 μg/ml; LGR5 knockdown decreases viability at higher concentrations (e.g., ≥ 24 μg/ml in the excerpt).
Time-response (3 μg/ml cisplatin): LGR5 overexpression increases viability after ≥48h treatment; knockdown reduces viability at ≥48h.
Population shift after cisplatin: after treating with 3 μg/ml for 2 days then culturing for 2 weeks, the percentage of LGR5+ expands from ~1.76% to ~12.36% in SiHa-AcGFP; from ~74.21% to ~99.57% in SiHa-LGR5; and similarly in HeLa populations.

Skeptical nuance / missing mechanistic specificity: The excerpt does not include mechanistic readouts for DNA damage repair, apoptosis signaling, drug efflux transporters, or cell cycle changes after cisplatin—so the link is phenotypic (survival + CSC traits) and pathway-coupled via Wnt/sphere assays, but not mechanistically decomposed for cisplatin.

5) Threats to validity & reproducibility (paper-specific, evidence-based)

These concern scores are not extracted from the paper; they are my skeptical synthesis based on the explicit modeling scope described in the provided text: two cervical cancer lines, immunodeficient mice, and reliance on tumorsphere/self-renewal + Wnt-modulator tools for mechanistic linkage.

6) What would disprove/change the main conclusions?

If independent assays (orthogonal gene perturbations) failed to reproduce the LGR5-driven shifts in tumorsphere formation, in vivo tumor-initiation frequency, and cisplatin viability, the central directionality would be weakened.
If DKK-1/CHIR-99021 modulated spheres independently of LGR5 status (i.e., no interaction), then the pathway mediation claim would be less supported.

Author review links (run by you on BGPT)

Open these for author-specific critical viewpoints and cross-paper context.

Feedback:

Updated: April 06, 2026